| Literature DB >> 28812410 |
Ilka Kamrad1, Åke Carlsson1, Anders Henricson2, Håkan Magnusson1, Magnus K Karlsson1, Björn E Rosengren1.
Abstract
Background and purpose - Total ankle replacement (TAR) is gaining popularity for treatment of end-stage ankle arthritis. Large patient-centered outcome studies are, however, few. Here, we report data from the Swedish Ankle Registry. Patients and methods - We examined outcomes after primary TAR in patients from the Swedish Ankle Registry using PROMs (Patient Reported Outcome Measures; generic: EQ-5D and SF-36, region specific: SEFAS (Self-Reported Foot and Ankle Score), and a question on satisfaction). We included 241 patients registered with primary TAR between 2008 and 2016 and who completed PROMs preoperatively and postoperatively up to 24 months. We evaluated changes in PROMs following surgery and estimated effects of age, diagnosis, prosthetic design, and preoperative functional score on the outcomes. Results - All absolute scores improved from preoperative to 24 months after surgery (p ≤ 0.001). 71% of the patients were satisfied or very satisfied at the latest follow-up and 12% dissatisfied or very dissatisfied. Postoperative SEFAS correlated with age (r = 0.2, p = 0.01) and preoperative SEFAS (r = 0.3, p < 0.001), as did patient satisfaction (r = -0.2; p ≤ 0.03). Postoperative SEFAS and EQ-5D were similar between different diagnoses or prosthetic designs. Preoperative SF-36 was associated with diagnosis (p ≤ 0.03), postoperative SF-36 with age (r = 0.2, p = 0.01) and diagnosis (p < 0.03). Interpretation - We found statistically and clinically significant improvements in patient-reported outcomes following TAR surgery. The postoperative region-specific SEFAS was positively associated with older age. Prosthetic design seemed not to influence patient-reported outcome, whereas diagnosis partly did. Studies with longer follow-up are necessary to establish the long-term outcome of TAR and to elucidate whether short- and mid-term outcomes may predict implant failure.Entities:
Mesh:
Year: 2017 PMID: 28812410 PMCID: PMC5694814 DOI: 10.1080/17453674.2017.1366405
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Diagnosis, sex, and mean age of 241 patients
| Diagnosis | Women | Men | Total | Mean age (SD) |
|---|---|---|---|---|
| Osteoarthritis | 20 | 39 | 59 | 68 (8) |
| Rheumatoid arthritis | 59 | 8 | 67 | 60 (13) |
| Posttraumatic arthritis | 48 | 42 | 90 | 62 (10) |
| Other | 11 | 14 | 25 | 58 (12) |
| Total | 138 | 103 | 241 | 62 (11) |
Patient-reported outcome measure (PROM) scores. Values are mean (SD)
| Postopertive score | ||||
|---|---|---|---|---|
| PROM n = | Preop. 220–236 | 6 months 116–127 | 12 months 166–183 | 24 months 150–167 |
| SEFAS | 16 (7) | 28 (10) | 30 (10) | 31 (9) |
| EQ-5D | 0.4 (0.3) | 0.6 (0.3) | 0.7 (0.3) | 0.7 (0.3) |
| EQ-VAS | 54 (22) | 67 (20) | 71 (19) | 73 (18) |
| SF-36 ph | 34 (20) | 51 (24) | 55 (25) | 59 (24) |
| SF-36 bp | 30 (15) | 51 (23) | 58 (25) | 59 (24) |
| SF-36 PCS | 29 (9) | 36 (12) | 39 (12) | 40 (11) |
| SF-36 MCS | 49 (16) | 53 (13) | 52 (14) | 53 (13) |
SF-36 ph: physical functioning, bp: bodily pain,
PCS: physical component summary scale,
MCS: mental component summary scale.
Not all patients completed all questionnaires.
Association between postoperative outcome and age, diagnosis, and prosthetic design
| Factor | SEFAS at 24 months | Δ SEFAS | EQ-5D at 24 months | Δ EQ-5D | Satis- faction |
|---|---|---|---|---|---|
| Age | |||||
| r | 0.2 | 0.2 | 0.1 | –0.08 | –0.2 |
| p-value | 0.01 | 0.01 | 0.09 | 0.3 | 0.02 |
| Diagnosis | |||||
| p-value | 0.1 | 0.03 | 0.2 | 0.2 | 0.4 |
| Prosthetic design | |||||
| p-value | 0.3 | 0.2 | 0.5 | 0.6 | 0.4 |
r: correlation coefficient.
Change preoperative to 24 months.
Correlation analyses
ANOVA with post-hoc analyses.
No post-hoc group differences.
ANOVA analyses
Association between SF-36 and age, diagnosis, and prosthetic design
| Age | Diagnosis | Prosthetic design p-value | |||
|---|---|---|---|---|---|
| SF-36 subscore | r | p-value | p-value | Tukey post-hoc test | |
| Preoperative | |||||
| ph | 0.01 | 0.9 | < 0.001 | ≤ 0.001 | |
| bp | 0.1 | 0.08 | 0.01 | 0.01 | |
| PCS | 0.03 | 0.7 | < 0.001 | ≤ 0.002 | |
| MCS | 0.07 | 0.3 | 0.03 | 0.03 | |
| 24 months postoperative | |||||
| ph | 0.1 | 0.5 | 0.001 | ≤ 0.003 | 0.7 |
| bp | 0.2 | 0.01 | 0.7 | 0.8 | |
| PCS | 0.1 | 0.2 | 0.04 | 0.03 | 0.8 |
| MCS | 0.1 | 0.1 | 0.2 | 0.4 | |
| Preop to 24 months postop | |||||
| ph | 0.1 | 0.4 | 0.3 | 0.7 | |
| bp | 0.1 | 0.1 | 0.7 | 0.1 | |
| PCS | 0.1 | 0.2 | 0.06 | 0.9 | |
| MCS | –0.003 | 0.9 | 0.8 | 0.8 | |
SF-36 ph: physical functioning; bp: bodily pain;
PCS: physical component summary scale;
MCS: mental component summary scale.
r: correlation coefficient.
ANOVA.
p < 0.001 difference between RA (lower scores) and PTA and OA.
p = 0.01 difference between RA (lower scores) and PTA.
p ≤ 0.002 difference between RA (lower scores) and all other diagnoses.
p = 0.03 difference between PTA and OA (both higher scores) and other diagnoses.
p = ≤ 0.003 difference between RA (lower scores) and PTA and OA.
p = 0.03 difference between RA (lower scores) and OA.
Changes in patient-reported outcome (PROM) scores
| Mean difference (95% CI) between | ||||
|---|---|---|---|---|
| PROM | preop. and 24 months postop. | p-value | 6 months and 24 months postop. | p-value |
| SEFAS | 15 (14–17) | < 0.001 | 2.5 (0.7 to 4.4) | 0.01 |
| EQ-5D | 0.3 (0.2–0.3) | 0.05 | 0.02 (–0.04 to 0.07) | 0.6 |
| EQ-VAS | 19 (15–23) | < 0.001 | 3 (0 to 4) | 0.08 |
| SF-36 ph | 23 (19–26) | < 0.001 | 7 (3 to 11) | 0.001 |
| SF-36 bp | 26 (22–30) | 0.01 | 3 (–2.5 to to 9) | 0.3 |
| SF-36 PCS | 10 (9–12) | < 0.001 | 2 (0 to 5) | 0.07 |
| SF-36 MCS | 4 (2–6) | < 0.001 | –0.5 (–4 to 3) | 0.8 |
SF-36 ph: physical functioning, bp: bodily pain;
PCS: physical component summary scale;
MCS: mental component summary scale.
paired t-tests.